0.346  -0.009 (-2.54%)		04-25 16:00
Open: 0.3501 High: 0.3501 Volume: 2,890,752		Pre. Close: 0.355 Low: 0.34 Market Cap: 263(M)

Short term
Mid term
Targets	6-month :	0.48	1-year :	0.54
Resists	First :	0.41	Second :	0.46
Pivot price	0.38
Supports	First :	0.33	Second :	0.28
MAs	MA(5) :	0.35	MA(20) :	0.39
	MA(100) :	0.38	MA(250) :	0.39
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	8.9	D(3) :	8.6
RSI	RSI(14): 36.3
52-week	High :	0.73	Low :	0.2

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CYBN ] has closed above bottom band by 17.0%. Bollinger Bands are 14.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.35 - 0.35	0.35 - 0.35
Low:	0.33 - 0.34	0.34 - 0.34
Close:	0.34 - 0.35	0.35 - 0.35

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Thu, 25 Apr 2024
Cybin to Participate at the 27th Annual Milken Institute Global Conference - Business Wire

Thu, 21 Mar 2024
Cybin Raises $150M to Advance Psychedelic Therapy for Depression - HIT Consultant

Tue, 19 Mar 2024
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million - Business Wire

Mon, 18 Mar 2024
Cybin, Inc. Shines at Dallas Investor Event - TipRanks.com - TipRanks

Wed, 13 Mar 2024
Cybin Inc. Secures $150M for Depression Drug - TipRanks.com - TipRanks

Tue, 27 Feb 2024
Cybin to Present at the TD Cowen 44th Annual Health Care Conference - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	406 (M)
Shares Float	352 (M)
Held by Insiders	12 (%)
Held by Institutions	6.8 (%)
Shares Short	12,400 (K)
Shares Short P.Month	10,770 (K)

EPS	-0.19
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.18
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-51.7 %
Return on Equity (ttm)	-90.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.13
Qtrly Earnings Growth	0 %
Operating Cash Flow	-44 (M)
Levered Free Cash Flow	-25 (M)

PE Ratio	-1.93
PEG Ratio	0
Price to Book value	1.82
Price to Sales	0
Price to Cash Flow	-3.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.